163 related articles for article (PubMed ID: 7664501)
1. Economics of lipid lowering with HMG CoA reductase inhibitors.
Illingworth DR
Clin Cardiol; 1995 Jun; 18(6):295, 363. PubMed ID: 7664501
[No Abstract] [Full Text] [Related]
2. Cost-effectiveness analysis of lipid-modifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease.
Jolain B; Pettitt D
Clin Ther; 1995; 17(3):572-80. PubMed ID: 7585861
[No Abstract] [Full Text] [Related]
3. Update on the treatment of hypercholesterolemia, with a focus on HMG-CoA reductase inhibitors and combination regimens.
Ginsberg HN
Clin Cardiol; 1995 Jun; 18(6):307-15. PubMed ID: 7664504
[TBL] [Abstract][Full Text] [Related]
4. [In process].
Reisdorf S
Med Monatsschr Pharm; 2017 Jun; 40(6):271-3. PubMed ID: 29979855
[No Abstract] [Full Text] [Related]
5. Cost effectiveness of treatment to National Cholesterol Education Panel (NCEP) targets with HMG-CoA reductase inhibitors. Trial design.
Black D; Davidson M; Koren M; Bakker-Arkema R; Tresh P; McLain R; Smith D; Hunninghake D
Pharmacoeconomics; 1997 Aug; 12(2 Pt 2):278-85. PubMed ID: 10170452
[TBL] [Abstract][Full Text] [Related]
6. Reducing expenditures for statin-type lipid-lowering agents.
Am J Health Syst Pharm; 1998 May; 55(10):995-6, 999. PubMed ID: 9606450
[No Abstract] [Full Text] [Related]
7. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.
Hsu I; Spinler SA; Johnson NE
Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093
[TBL] [Abstract][Full Text] [Related]
8. [ALLHAT [Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial]].
Tomiyama H; Doba N
Nihon Rinsho; 2001 Mar; 59 Suppl 3():393-7. PubMed ID: 11347101
[No Abstract] [Full Text] [Related]
9. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia.
Hilleman DE; Phillips JO; Mohiuddin SM; Ryschon KL; Pedersen CA
Clin Ther; 1999 Mar; 21(3):536-62. PubMed ID: 10321422
[TBL] [Abstract][Full Text] [Related]
10. [HMG-CoA reductase inhibitors].
Yamamoto A
Nihon Rinsho; 2001 Mar; 59 Suppl 3():578-86. PubMed ID: 11347135
[No Abstract] [Full Text] [Related]
11. Lipid-lowering drugs.
Med Lett Drugs Ther; 2016 Oct; 58(1506):133-140. PubMed ID: 27755510
[No Abstract] [Full Text] [Related]
12. Targeted prevention of coronary artery disease: pharmacological considerations in multimodality treatment.
Shviro I; Leitersdorf E
Cardiology; 1996; 87(6):469-75. PubMed ID: 8904672
[TBL] [Abstract][Full Text] [Related]
13. Fighting high cholesterol levels--lipid lowering drugs.
Fidge NH
Med J Aust; 1993 Dec 6-20; 159(11-12):815-9. PubMed ID: 8264477
[No Abstract] [Full Text] [Related]
14. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Economics and cost-effectiveness in evaluating the value of cardiovascular therapy: lipid-lowering therapies--an industry perspective.
Jackson JD
Am Heart J; 1999 May; 137(5):S105-10. PubMed ID: 10220609
[No Abstract] [Full Text] [Related]
15. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Lipid-lowering drugs, cost-effectiveness data, and the formulary system: a health systems perspective.
Kessler JM
Am Heart J; 1999 May; 137(5):S111-4. PubMed ID: 10220610
[No Abstract] [Full Text] [Related]
16. Advances in treatment of cholesterol abnormalities. The role of HMG-CoA reductase inhibitors.
Rackley CE
Postgrad Med; 1996 Nov; 100(5):61-5, 70-2. PubMed ID: 8917325
[TBL] [Abstract][Full Text] [Related]
17. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
18. Economic aspects of hypercholesterolemia treatment with HMG-CoA reductase inhibitors: a review of recent developments.
MacNeil P
Can J Cardiol; 1998 Apr; 14 Suppl A():14A-16A. PubMed ID: 9594928
[TBL] [Abstract][Full Text] [Related]
19. Needed: pragmatic clinical trials for statin-intolerant patients.
Maningat P; Breslow JL
N Engl J Med; 2011 Dec; 365(24):2250-1. PubMed ID: 22085320
[No Abstract] [Full Text] [Related]
20. Lipid-lowering drugs: focus on HMG-CoA reductase inhibitors. Introduction.
Thompson GR
Atherosclerosis; 1991 Dec; 91 Suppl():S1-2. PubMed ID: 1789811
[No Abstract] [Full Text] [Related]
[Next] [New Search]
